Ignite Creation Date:
2024-05-06 @ 7:58 PM
Last Modification Date:
2024-10-26 @ 3:17 PM
Study NCT ID:
NCT06202001
Status:
RECRUITING
Last Update Posted:
2024-04-02
First Post:
2024-01-02
Brief Title:
Irinotecan TAS-102 Plus Bevacizumab as a Second-Line Therapy in mCRC Patients
Sponsor:
Organization:
Cancer Institute and Hospital Chinese Academy of Medical Sciences